chronic oral etoposid etoposid import drug agent cur treatment patient advanc neoplasm germ cell tumor non-hodgkin lymphoma nhl small cell lung cancer sclc etoposid remark schedul depend random comparison impress surviv differ patient extens sclc cours cours previou clinic laboratori data etoposid schedul drug author sever etoposid studi extend administr schedul prolong schedul superior standard schedul phase result etoposid day feasibl moder toxic sever phase II studi complet studi patient sclc nhl germ cell tumor soft tissu sarcoma renal carcinoma ovarian carcinoma respons group patient sclc lymphoma germ cell tumor group respons patient resist standard schedul patient resist high-dos etoposid bone marrow transplant investig indiana univers medic center oral etoposid similar fashion patient advanc germ cell tumor sclc result similar author number combin chemotherapi program chronic oral form etoposid patient sclc non-smal cell lung cancer elderli patient high-grad intermedi form nhl addit chronic intraven oral etoposid salvag approach patient acut myelocyt leukemia recurr resist intermediate-grad high-grad nhl preliminari pharmacokinet data oral dose bioavail prolong oral cours mani patient minimum plasma concentr microgram/ml further studi multipl dose continu infus etoposid critic plasma level progress etoposid way new drug mani featur differ activ spectrum 